UMC Utrecht and VectorY Therapeutics collaborate in ALS Biomarker Study
UMC Utrecht has enrolled its first patient for a new study to identify biomarkers of Amyotrophic Lateral Sclerosis (ALS). The observational investigator-initiated study is led by Professor Dr. Leonard van…
Updated Results Shared for Sanofi’s Blood Cancer Trial SAR443579/IPH6101
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced today the latest efficacy and safety updates from the Phase 1/2 trial of SAR443579/IPH6101 (SAR’579), a CD123 targeting NKp46/CD16-based Natural Killer…
Celltrion Presents Positive Phase III Results of CT-P47 for Rheumatoid Arthritis at EULAR 2024
Celltrion Unveils Positive Phase III Results of CT-P47 Biosimilar for Rheumatoid Arthritis at EULAR 2024 Celltrion has revealed encouraging findings from its Phase III study of CT-P47, a biosimilar referencing…
Celltrion Unveils Promising Phase III Results for CT-P47, a Biosimilar to RoActemra®, in RA Patients at EULAR 2024
Celltrion today presented positive Phase III data for CT-P47, a biosimilar referencing RoActemra® in patients with moderate-to-severe rheumatoid arthritis (RA), at the Annual European Congress of Rheumatology (EULAR) 2024. The…
Genentech’s Phase III STARGLO Study: Columvi Extends Survival in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Genentech, part of the Roche Group, announced significant results from its Phase III STARGLO study of Columvi® (glofitamab-gxbm) with gemcitabine and oxaliplatin (GemOx) versus Rituxan® (rituximab) with GemOx (R-GemOx) in…
BeiGene to Present SEQUOIA Study Data on BRUKINSA® and Venetoclax in High-Risk CLL/SLL at EHA2024
BeiGene Presents New Data on BRUKINSA® and Venetoclax Combination for High-Risk CLL/SLL at EHA2024 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced the presentation of…
Sparrow Pharma Shares Phase 2 Trial Data on Clofutriben and Prednisolone for Polymyalgia Rheumatica at EULAR 2024
Sparrow Pharmaceuticals presented data from an ongoing Phase 2 trial of the HSD-1 inhibitor clofutriben (SPI-62) and prednisolone for polymyalgia rheumatica (PMR) at EULAR 2024 in Vienna, Austria (June 12-15).…
Presentation of New SEQUOIA Study Findings: BRUKINSA® and Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global leader in oncology, has unveiled new findings from the SEQUOIA study of BRUKINSA® (zanubrutinib) today at EHA2024 in Madrid, Spain.…
Kirin Holdings Commences Tender Offer To Make FANCL A Wholly-Owned Subsidiary
Kirin Holdings Company, Limited (Kirin Holdings) (TOKYO: 2503) has announced its intention to acquire additional shares of common stock of FANCL Corporation (FANCL) (TOKYO: 4921) through a tender offer and…
Enveda Biosciences Secures $55 Million to Boost Platform Development and Propel Multiple Candidates towards Clinical Trials
Enveda Biosciences Secures $55M to Advance AI-Driven Drug Development Enveda Biosciences, known for its pioneering use of AI in drug discovery, has announced a $55 million financing round. This round,…
WHO Alarmed by Worsening Health Emergency in West Bank
WHO remains concerned about the escalating health crisis in the occupied Palestinian territory, including the West Bank, where attacks on health infrastructure and increased restrictions on movement are obstructing access…
WHO Introduces Updated Guidelines for Fiscal Policies Promoting Healthy Diets
The World Health Organization has released a new guideline outlining effective strategies to foster food environments that support healthy dietary choices. Emphasizing fiscal policies as a pivotal tool, the guideline…